Lee Roy Morgan, MD, PhD, is a clinical pharmacologist and oncologist whose research and clinical interests have focused on the development of new and novel agents that are effective against both primary and metastatic malignancies involving the brain and spinal nervous system. Dr. Morgan received his B.S. (1958), MS (1959) and PhD (1960) degrees in chemistry from Tulane University, New Orleans, and completed post-doctoral studies in chemistry at Imperial College, University of London (1961). In 1971, he received a MD degree from LSU Medical School. From 1961 -1986 he was on the faculty at LSU Medical School. He retired as professor of pharmacology and medicine and chairman of the Department of Pharmacology there in 1986. From 1973 - 2005, he also practiced oncology and retired in 2005 to focus full time on his R & D company - DEKK-TEC Inc. He was a Visiting Scientist in Molecular Pathology at MD Anderson Medical Center, Houston, TX (2005). Currently, he is CEO of DEKK-TEC, an adjunct research professor of chemistry at UNO, and an adjunct clinical professor of medicine at Tulane Medical Center.
Morgan LR, Weiner RS, Ware ML, Bandhari M, Mahmood T, Friedlander P, Rodgers A. Comparative pharmacokinetics for 4-demethyl-4-cholesteryloxypenclomedine (DM-CHOC-PEN) in adolescent and young adults (AYA) vs. adult subjects with advanced malignancies involving the CNS. Amer J Pharm, 35:122, 2019.
Morgan LR, Weiner, RS, Ware ML, Bhandari M, Mahmood T, Friedlander P. Early phase I clinical trial results for the tolerance and safety of 4-demethyl-4-cholesteryloxypenclomedine (DM-CHOC-PEN) in adolescent and young adult (AYA) subjects with advanced malignancies. J Cancer Research Updates, 7:75, 2018.
Weiner RS, Ware ML, Bhandari M, Mahmood T, Friedlander P, Morgan LR. The tolerance and safety of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in adolescent and young adult (AYA) subjects with advanced malignancies. J Translational Sciences, 3:1, 2017.
Morgan LR, Struck RF. Comparative preclinical pharmacology and toxicology for 4-HOOI: a potential neuro-alkylating agent for glioblastoma and metastatic cancers of the central nervous system. In: Treatments of CNS Tumors, Ed. Lee Roy Morgan, InTech Publishing, Croata, pp. 23-47, 2016.
Rosenlof T, Strong MJ, Padmanabha S, Weiner RS, Morgan LR, Ware ML. Treatment of recurrent metastatic uterine leiomyosarcoma of the spine: a multimodality approach using surgical resection, radiosurgery, and chemotherapy. Spine, 79: 25, 2015.
Morgan LR, Rodgers AH, Bastian G, Benes E, Waud WR, Jursic BS, Struck RF, LaHoste G, Thornton M, Luttrell M, Stevens E, Thompson R. Comparative preclinical pharmacology and toxicology for 4-demethyl-4-cholestryloxycarbonylpenclomedine (DM-CHOC-PEN): a potential neuro-alkylating agent for glioblastoma and metastatic cancers of the central nervous system. In: CNS Tumors, Ed. Lee Roy Morgan, InTech Publishing, Croata, pp. 122-133, 2014.
Morgan LR. A rationale for novel anti-neurooncology drugs. Chapter 15. In: Evolution of the Molecular Biology of Brain Tumors and The Therapeutic Implications, Ed. Terry Lichtor, InTech Publishing, Croata, pp. 435-458, 2013.
Morgan LR, Benes E, Rodgers AH, Jursic BS, Struck BF, Waud WR, Weiner RS, Ware M, Friedlander P. Interaction of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC_PEN) with melanoma melanin metabolism and cell death. European J Cancer, 205:211, 2011.
Adams DJ, Waud WR, Wani MC, Manikumar G, Flowers JL, Driscoll TA Morgan LR. BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. Cancer Chemother and Pharmacol, 67(4):855, 2011.
Morgan LR, Southerland C, Krementz ET, Schein PS, Woolley DA. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep, 60:1437, 1976.